
|Articles|October 27, 2008
Oculus imaging device approved by FDA
The PARK 1 (Pachymeter/Autorefractor/Keratometer) imaging device (Oculus) has received premarket approval from the FDA.
Advertisement
The PARK 1 (Pachymeter/Autorefractor/Keratometer) imaging device (Oculus) has received premarket approval from the FDA.
The slim, ergonomically-designed device features a 5.7" LCD display, and comprises an autorefractor combined with a Scheimpflug based non-contact pachymeter, to photograph and measure corneal thickness and lens refractive power. It can be set to PARK, ARK or P measurement modes.
The PARK 1 will be launched officially at this year's American Academy of Ophthalmology (AAO) meeting, which is to be held on November 8–11 in Atlanta, GA, US.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
2
EURETINA 2026: Optogenetic therapy MCO-010 aims to restore vision in advanced macular disease
3
Oku Digital Health launches from Topcon to link eye care, primary care
4
Real-world VOYAGER data on faricimab in nAMD, DME, RVO at EURETINA 2026
5



















